Zhao L H, Lin Q L, Wei J, Huai Y L, Wang K J, Yan H Y
Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):692-701. eCollection 2015.
Currently, it is difficult to predict the prognosis of patients exhibiting stage II or stage III colorectal cancer (CRC) and to identify those patients most likely to benefit from aggressive treatment. The current study was performed to examine the clinicopathological significance of CD44 and CD44v6 protein expression in these patients.
We retrospectively investigated 187 consecutive patients who underwent surgery with curative intent for stage II to III CRC from 2007 to 2013 in the Beijing Civil Aviation Hospital. CD44 and CD44v6 protein expression levels were determined using immunohistochemistry and compared to the clinicopathological data.
Using immunohistochemical detection, CD44 expression was observed in 108 (57.75%) of the CRC patients; and its detection was significantly associated with greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological tumor-lymph node-metastasis (TNM) stage. CD44v6 expression was observed in 135 (72.19%) of the CRC patients; and its expression was significantly associated with a poorly differentiated histology, greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological TNM stage. Expression of CD44v6 was higher than that of CD44 in stage II and stage III sporadic CRC.
CD44v6 is a more useful marker for predicting a poor prognosis in stage II and stage III sporadic CRC as compared to CD44.
目前，预测II期或III期结直肠癌（CRC）患者的预后以及识别最有可能从积极治疗中获益的患者具有一定难度。本研究旨在探讨CD44和CD44v6蛋白表达在这些患者中的临床病理意义。
我们回顾性调查了2007年至2013年在北京民航医院接受II至III期CRC根治性手术的187例连续患者。采用免疫组织化学方法测定CD44和CD44v6蛋白表达水平，并与临床病理数据进行比较。
通过免疫组织化学检测，在108例（57.75%）CRC患者中观察到CD44表达；其检测结果与更大的浸润深度、淋巴结转移、血管淋巴管浸润以及更晚期的病理肿瘤-淋巴结-转移（TNM）分期显著相关。在135例（72.19%）CRC患者中观察到CD44v6表达；其表达与低分化组织学、更大的浸润深度、淋巴结转移、血管淋巴管浸润以及更晚期的病理TNM分期显著相关。在II期和III期散发性CRC中，CD44v6的表达高于CD44。
与CD44相比，CD44v6是预测II期和III期散发性CRC预后不良更有用的标志物。
